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Thyrotoxic Heart Disease
CHUNG-WAH SIU, HUNG-FAT TSE, CHU-PAK LAU
From Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong,
Hong Kong SAR
SIU ET AL.: Thyrotoxic Heart Disease. The close link between the thyroid gland and the heart has been well
recognized since the first description of thyrotoxicosis in nearly 200 years ago. Despite this well known
association, there have been only a few population based studies performed on thyrotoxic heart disease except
thyrotoxic atrial fibrillation. Even so, there has not been any consensus for the definition for "thyrotoxic heart
disease". For other cardiac manifestations of thyrotoxicosis including thyrotoxic cardiomyopathy and thyrotoxic
pulmonary hypertension, only occasion case reports can be found in the current medical literatures. Their
natural history, clinical course and outcomes are largely unknown. On the other hands, there is an enlarging
body of evidence suggesting a direct pathogenic role of thyrotoxicosis per se as the sole cause of these thyrotoxic
heart diseases. In this review, we briefly discuss the three cardiac consequences of thyrotoxicosis, namely
atrial fibrillation, congestive cardiac failure and pulmonary hypertension. (J HK Coll Cardiol 2005;13:16-20)
Atrial fibrillation, cardiac failure, thyrotoxicosis
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Introduction
Thyrotoxicosis is a common medical condition
with prevalence of 2 percents in female and 0.2-0.3
percent in male. 1 The close link between the thyroid
gland and the heart was evident since the first
description of thyrotoxicosis for nearly two hundred
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years ago. 2 Many of the clinical manifestations of
thyrotoxicosis are due to the ability of thyroid
hormone to alter cardiovascular hemodynamic.3 The
usual coined terms to describe the association of
thyrotoxicosis and its cardiac manifestations include
"thyrotoxic heart disease", "thyro-cardiac disease"
and "thyro-heart disease". Despite the frequent
appearances of these terms in medical literatures,
there has been no consensus of its definition. For
simplicity, we may define "thyrotoxic heart disease"
as the association between thyrotoxicosis and its
cardiovascular complications. In this review, we
briefly discuss the three cardiac consequences of
thyrotoxicosis, namely atrial fibrillation, congestive
cardiac failure and pulmonary hypertension.
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Atrial fibrillation
Prevalence
Atrial fibrillation (AF) is the most well-known
cardiovascular complication in thyrotoxic patients and
its clinical importance often overshadows the most
common rhythm disturbance, sinus tachycardia in this
population. Atrial fibrillation occurs in 5 to 20 percent
of patients with thyrotoxicosis.4-8 On the other hands, as
many as 13 percent of patients with unexplained atrial
fibrillation have biochemical evidence of thyrotoxicosis.9
In these studies, they consistently showed that the
prevalence of atrial fibrillation increased with age in
thyrotoxic population as in general population. Also,
in one of the most frequently cited study by Sandler
and Wilson published nearly half century ago, the
authors observed that the prevalence of atrial fibrillation
was higher among thyrotoxic men than women.10 More
recently, Shimizu et al described the prevalence of atrial
fibrillation in a large cohort of 13,088 thyrotoxic patients
in Ito hospital in Tokyo.11 They showed that the annual
incidence of atrial fibrillation was only 1.7%, much
lower than previous studies. However, similar to
previous studies, the incidence of atrial fibrillation
increased with age and was higher in male thyrotoxic
subjects. Unfortunately, only age and sex were analyzed
in this particular study but other co-morbidities and
potential confounding factors had not been adjusted.

Mechanisms
In general, for atrial fibrillation to develop, three
basic components are required: 1) a specific triggers;
2) a suitable substrate; and 3) modifying factors.
Haissagurere et al. have demonstrated that a single source
of rapid impulses, mainly originating from the
pulmonary veins,12 is the majority source of trigger for
the initiation and maintenance of AF in patients with
paroxysmal AF. In thyrotoxic rat model, thyroid
hormone has been shown to increase automaticity and
enhance triggered activity of pulmonary vein which may
increase its arrhythmogenic activity similar to that
observed by Haissagurere group. 13 Besides, thyroid
hormone also modifies the electrophysiological
properties of the atrium: shortening the atrial action
potential duration and atrial refractory period, creating
substrate favor the maintenance of atrial fibrillation. In
J HK Coll Cardiol, Vol 13

addition, modifying factors particularly autonomic tone
also play contributory role in the pathogenesis of atrial
fibrillation in previous studies. Both parasympathetic
and sympathetic stimulation shorten the atrial
refractoriness which is associated with induction and
maintenance of AF.

Outcomes
It is usually assumed that successful treatment of
thyrotoxicosis often associates with reversion of sinus
rhythm spontaneously. However, there are only a few
studies in medical literatures providing information for
this issue. Nakazawa et al showed that 62% thyrotoxic
patients with atrial fibrillation had spontaneous sinus
conversion within the first 3 to 4 months after
euthyroidism, even without anti-arrhythmic agents in
1982.14 Also, atrial fibrillation is unlikely to revert to
sinus rhythm beyond this period without cardioversion.
For those thyrotoxic patients with persistent atrial
fibrillation after euthyroidism achieved, DC
cardioversion is highly effective for sinus conversion
(~90%) and sinus rhythm maintenance rates were
exceedingly high (56% at tenth year) compared to nonthyrotoxic atrial fibrillation population whom underwent
cardioversion.15
One of the most devastating consequences of
atrial fibrillation is the systemic thromboembolism
including stroke. However, whether thyrotoxic atrial
fibrillation population is at increased risk for systemic
thromboembolism has not been clearly evaluated for the
time being. Two retrospective studies, both were
conducted more 15 years ago, revealed a higher embolic
rate in those with atrial fibrillation than those in sinus
rhythm among thyrotoxic population.16,17 However, in
one of these two studies, age rather than the presence of
atrial fibrillation, was the main risk factor for
thromboembolism.16 So far, there is no large prospective
population study to confirm this observation.

Congestive Cardiac Failure
Although clinical heart failure can occasionally
happen in the setting of thyrotoxicosis, most patients
with clinical overt heart failure are simply because of
persistent sinus tachycardia or atrial fibrillation, their
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left ventricular systolic function is usually normal. It is
understandable that for those patients with preserved left
ventricular function, the clinical congestive cardiac
failure may well be secondary to rapid atrial fibrillation
and possibly an element of diastolic dysfunction.
However, in the setting of atrial fibrillation, the
contribution of left ventricular diastolic dysfunction is
rather difficult to assess. It was for many years, assumed
that this condition was seen only in the presence of
underlying cardiovascular disease. In recent years,
occasional case reports and case series were found in
medical literatures, describing thyrotoxicosis as a cause
of "reversible" dilated cardiomyopathy.18-20 However,
there has been an emerging concept, introduced by
Levine and his coworkers, on the basis of their clinical
observations of patients in whom thyrotoxicosis was
the sole or principal factor leading to clinical overt heart
failure and cardiomyopathy.21,22 However, because of the
"rarity" of this clinical entity, the incidences of clinical
congestive cardiac failure and dilated cardiomyopathy
in thyrotoxic patients are not available in current medical
literatures. In addition, their nature, prognosis and
reversibility remained largely unknown.
In recent years, an enlarging body of knowledge
from both human and animal studies suggesting the
existence of the entity of "pure thyrotoxic dilated
cardiomyopathy". Substantial body of evidence indicates
that an excess thyroid hormone alone can cause cardiac
failure in a number of species.23 Forfar and associates
had assessed the effects of exercise on left ventricular
ejection fraction measured by radio-nucleotide
ventriculography in human cases with spontaneous
uncomplicated hyperthyroidism.24 They found that in
hyperthyroid state, patients exhibited a high left
ventricular ejection fraction at rest but paradoxically,
the EF fell significant during exercise. At the same
workload and heart rate during euthyroid state, patients
restored a normal rise in left ventricular ejection fraction
upon exercise. These findings suggested hyperthyroid
state may result in the poor cardiac reserve despite
normal resting EF.
Changes in thyroid hormone status influence
cardiac action by three different routes: 1) thyroid
hormone exerts a direct effect on cardiac myocytes
primarily by binding to nuclear T3 receptors influencing
cardiac gene expression 2) thyroid hormone increases
18

the sensitivity of the sympathetic system in the
hyperthyroid heart and 3) thyroid hormone leads to
hemodynamic alterations in the periphery which results
in increased cardiac filling and modification of cardiac
contraction.
Most of the molecular and cellular mechanisms
responsible for cardiovascular effects by thyroid
hormone exert through both genomic and nongenomic
effects on cardiac myocytes (Figure 1). The genomic
effects of the thyroid hormone are mediated by the
transcriptional activation or repression of specific target
genes that encode both structural and functional proteins.
Once in the cardiac myocytes, T3 enters the nucleus and
interacts with specific transcriptional activators (nuclear
receptor α1) or repressors (nuclear receptor α2).
Occupancy of these receptors by T3, in combination with
recruited cofactors, allows the thyroid hormone-receptor
complex to bind (nuclear receptor α1) or release (nuclear
receptor α2) specific sequences of DNA (thyroidresponsive element, TRE), that, in turn, by acting as cisor trans-regulators, modify the rate transcription of
specific target gene. 25 Figure 1 summarized
transcriptional change in difference gene expression. One
example is that thyroid hormone altering the gene
expression in cardiac myocytes leads to changes in the
proportion of myosin heavy-chain protein from beta to
alpha, thereby increasing myosin V1 and decreasing
myosin V3 isozyme levels which may result in relatively
ineffective use of energy in ventricular myocardium.
On the other hands, hemodynamic changes
secondary to peripheral vascular effect of thyroid
hormone may further complicate the picture.6,26 As a
result of thyroid hormone on the heart and peripheral
vasculature, there is an increase in heart rate, blood
volume, left ventricular stoke volume, ejection fraction
and cardiac output. Peripheral vasodilatation occurs as
a result of rapid utilization of oxygen, increased
metabolic end products, and induction of arterial smooth
muscle cell relaxation by thyroid hormone directly.
Vasodilatation results in a decrease in systemic vascular
resistance by an average of 50-60%. The decrease in
systemic vascular resistance plays a central role in the
hyperthyroid hemodynamic changes. Vasodilatation and
lack of increase in renal blood flow cause a decrease in
renal perfusion pressure and an activation of the renninangiotensin system, thus increasing sodium reabsorption
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Figure 1. Genomic effects of thyroid hormone (T3) on cardiomyocytes NR, Triiodothyronine
nuclear receptor; TRE, thyroid hormone responsive element.

and thus the blood volume. This may at the end increase
the cardiac output by 2-3 folds.
It seems that in the hyperthyroid state, enormous
changes in the loading situation (both pre-load and afterload) together with structural changes of the cardiac
myocytes which may lead to decrease cardiac reserves,
in susceptible individuals, these factors may at the end
of days lead to the development of clinical overt cardiac
failure in the absence of underlying heart disease.

Pulmonary Hypertension
Since early 1980s, thyrotoxicosis has been
increasingly recognized as a rare cause of pulmonary
hypertension as accumulating case reports and case
series had been published describing this association.27-30
In most series, pulmonary arterial hypertension were
defined as the peak pulmonary systolic pressure
>35 mmHg and nearly exclusively derived with
echocardiographic technique. Similar to congestive
cardiac failure, there has no been any large prospective
population based study for this population therefore
J HK Coll Cardiol, Vol 13

incidence, nature, prognosis and reversibility of
thyrotoxic pulmonary hypertension remained largely
obscure.
Two possible mechanisms have been put forwards
to explain this association: 1) elevation of pulmonary
vascular resistance and 2) high cardiac output in
thyrotoxic state. It has been shown that there was a higher
prevalence of positive anti-thyroglobulin antibody
among thyrotoxic patients with isolated pulmonary
hypertension (8-folds) than in the general population.31
This observation leads to suggestion of possible
autoimmune phenomenon similar to primary pulmonary
hypertension, resulted in endothelial and vascular
damage in thyrotoxic pulmonary hypertension. However,
in the cases described by Cohen32 and Eleftheriadis,33
their patients presented with pulmonary hypertension
and frank right heart failure, initially thought to be
primary pulmonary hypertension but eventually found
to be a case of thyrotoxic pulmonary hypertension. The
interesting point is that in both cases, the pulmonary
pressure fell back to normal after euthyroidism achieved.
This makes the possibility of autoimmune process as a
cause of pulmonary vasculature damage and pulmonary
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hypertension rather remote. Recently, a prospective
Doppler echocardiographic study further confirmed the
reversibility of pulmonary hypertension in
thyrotoxicosis population.34 In a mean follow-up time
of 14±8 months, 33 thyrotoxic patients with pulmonary
hypertension had significant drop in pulmonary artery
systolic pressure after euthyroidism. However, it
remains obscure whether the thyroid hormone exerts
its effect directly on the pulmonary vasculature or the
increase in cardiac output in thyrotoxic state leading to
the elevation of pulmonary artery pressure, in which
both may be normalized after euthyroidism.

Summary
The intimate relationship of thyroid gland and the
heart can aggravate pre-existing heart disease or even
lead to thyrotoxic heart diseases including atrial
fibrillation, congestive cardiac failure, cardiomyopathy
and pulmonary hypertension. Despite well-recognized
in clinical practice, many essential clinical information
including the epidemiology, outcome and management
strategies, have not been fully elucidated.
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